Rare diseases
Investigational molecules
Locations
501 Canal Boulevard Suite A100, 94804-3522, United States
Research activity is centered on Fabry disease, with attention to alpha-galactosidase A replacement through gene therapy approaches and long-term clinical follow-up in affected subjects.
The sponsor’s clinical work in this area includes ongoing interest in durable treatment effects and extended safety monitoring for inherited metabolic disease.
Sangamo Therapeutics Inc. runs clinical trials in conditions such as Prophylaxis against transplant rejection, Fabry's disease, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Belgium
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
